Abstract The inhibition of human microsomal prostaglandin E2 (PGE2) synthase‐1 (mPGES‐1) is a promising therapeutic modality for developing next‐generation anti‐inflammatory medications. In this study, we present novel 2‐phenylbenzothiazole derivatives featuring heteroaryl sulfonamide end‐capping substructures as inhibitors of human mPGES‐1, with IC50 values in the range of 0.72–3.40 µM in a cell‐free assay of PGE2 formation. Notably, compound 21, featuring a quinoxalinedione ring in its sulfonamide segment, effectively suppresses PGE2 biosynthesis at a low micromolar concentration (IC50 = 0.72 µM) with exceptional selectivity against cyclooxygenase (COX)‐1, COX‐2, 5‐lipoxygenase (5‐LOX), and FLAP. This compound offers a novel chemical scaffold for developing safer and more effective anti‐inflammatory agents.